Development Progress
Development Progress
R&D Projects Registration Category Indication/Therapeutic Use Phase I Phase II Phase III Approved
PUDK-HGF Biological Products Category 1 Rest pain and/or ischemic ulcers in limbs due to severe ischemic disease of the lower extremities
Remazolam Besylate for Injection New Indication Chemical category 1 Sedation during intensive care unit (ICU)
PARP Inhibitors Chemical category 1 Ovarian cancer, breast cancer, lung cancer, etc